ArticleHistochemistry and cell biology2026
Methodological framework for chromogenic mRNA detection using in situ hybridization chain reaction.
Article in Histochemistry and cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- June in focus in HCB: advanced methodologies.Histochemistry and cell biology · 2026Article
- Chromogenic in situ HCR as a targeted translational interface for routine molecular histology.Histochemistry and cell biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In situ hybridization chain reaction (HCR) is a highly sensitive method for visualizing single-molecule messenger RNA (mRNA) using self-assembling hairpin DNA pairs. However, conventional in situ HCR is primarily optimized for fluorescence detection, limiting its applicability in routine pathology and in tissues with strong autofluorescence. In this study, we established a chromogenic in situ HCR protocol using short hairpin DNA that achieves sensitivity comparable to fluorescent in situ HCR. To achieve efficient amplification and avoid steric hindrance, we adopted an indirect labeling strategy in which hairpin DNA conjugated with haptens (biotin, digoxigenin, or fluorescein) is detected using enzyme-conjugated streptavidin or antibodies. We validated this approach across various mouse tissues, including the brain, kidney, and liver, and on both slide-mounted and free-floating sections. The protocol enabled the clear visualization of low-abundance transcripts such as Oxtr and Esr1. Furthermore, we demonstrated the versatility of this approach by performing duplex chromogenic staining for two mRNA targets and by combining in situ HCR with immunohistochemistry to visualize mRNA and protein simultaneously. This chromogenic in situ HCR retains the high sensitivity of HCR and adds the practical advantages of bright-field detection, thereby expanding the utility of in situ HCR in histological research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.